Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing

Nature Chemical Biology

Volumn 7, Issue 12, 2011, Pages 902-908

  Small, Ben G ^a,b   McColl, Barry W ^c   Allmendinger, Richard ^a   Pahle, Jorgen ^a   Lopez Casteon, Gloria ^a   Rothwell, Nancy J ^a   Knowles, Joshua ^a   Mendes, Pedro ^a,d   Brough, David ^a   Kell, Douglas B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; I KAPPA B KINASE INHIBITOR; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR;

ARTICLE; COMBINATORIAL CHEMISTRY; EVOLUTIONARY ALGORITHM; MACROPHAGE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 81355127286     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.689     Document Type: Article

References (50)

1. Nathan, C. & Ding, A. Nonresolving inflammation. Cell 140, 871-882 (2010).
2. Dinarello, C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
3. Dinarello, C.A. Biologic basis for interleukin-1 in disease. Blood 87, 2095-2147 (1996). (Pubitemid 26086851)
4. Luheshi N.M., Rothwell N.J., Brough D. Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy. Br. J. Pharmacol. 157 1318-1329 (2009).
5. Relton, J.K. & Rothwell, N.J. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res. Bull. 29, 243-246 (1992).
6. Lu, Y.-C., Yeh, W.-C. & Ohashi, P.S. LPS/TLR4 signal transduction pathway. Cytokine 42, 145-151 (2008).
7. Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).
8. Fell, D.A. & Thomas, S. Physiological control of metabolic flux: the requirement for multisite modulation. Biochem. J. 311, 35-39 (1995).
9. Jeon, Y.J. et al. Dexamethasone inhibits IL-1beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-?B/Rel and AP-1 activation. Immunopharmacology 48, 173-183 (2000). (Pubitemid 30608674)
10. Lehár, J., Stockwell, B.R., Giaever, G. & Nislow, C. Combination chemical genetics. Nat. Chem. Biol. 4, 674-681 (2008).
11. Feng, Y., Mitchison, T.J., Bender, A., Young, D.W. & Tallarico, J.A. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat. Rev. Drug Discov. 8, 567-578 (2009).
12. Paolini, G.V., Shapland, R.H., van Hoorn, W.P., Mason, J.S. & Hopkins, A.L. Global mapping of pharmacological space. Nat. Biotechnol. 24, 805-815 (2006). (Pubitemid 44086621)
13. Coello, C.A.C., Lamont, G.B. & Veldhuizen, D.A.V. Evolutionary Algorithms for Solving Multi-objective Problems (Springer, 2007).
14. Handl, J., Kell, D.B. & Knowles, J. Multiobjective optimization in bioinformatics and computational biology. IEEE/ACM Trans. Comput. Biol. Bioinform. 4, 279-292 (2007).
15. Knowles, J., Corne, D. & Deb, K. Multiobjective Problem Solving from Nature: From Concepts to Applications (Springer, 2008).
16. Bäck, T., Fogel, D.B. & Michalewicz, Z. Handbook of Evolutionary Computation (Institute of Physics Pub., 1997).
17. Goldberg, D.E. The Design of Innovation: Lessons From and For Competent Genetic Algorithms (Kluwer Academic Publishers, 2002).
18. Knight, C.G. et al. Array-based evolution of DNA aptamers allows modelling of an explicit sequence-fitness landscape. Nucleic Acids Res. 37, e6 (2008).
19. O'Hagan, S., Dunn, W.B., Brown, M., Knowles, J.D. & Kell, D.B. Closed-loop, multiobjective optimization of analytical instrumentation: gas chromatography/ time-of-flight mass spectrometry of the metabolomes of human serum and of yeast fermentations. Anal. Chem. 77, 290-303 (2005). (Pubitemid 40096698)
20. Knowles, J. closed-loop evolutionary multiobjective optimization. IEEE Comput. Intell. Mag. 4, 77-91 (2009).
21. Zitzler, E. & Künzli, S. Indicator-based selection in multi-objective search. in Parallel Problem Solving from Nature-PPSN VIII (eds. Yao, X. et al.) 832-842 (Springer, 2004).
22. Allmendinger, R. & Knowles, J. Analysis of Several Evolutionary Algorithms on the Noisy Three-Objective Chemical Mixture Optimization Problem. Technical Report MLO-12009, 1-9 (2009).
23. Allmendinger, R. & Knowles, J. Evolutionary optimization on problems subject to changes of variables. in Parallel Problem Solving from Nature-PPSN XI (eds. Schaefer, R., Cotta, C., Kolodziej, J. & Rudolph, G.) 151-160 (Springer, 2010).
24. Kell, D.B. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genomics 2, 2 (2009).
25. Kell, D.B. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch. Toxicol. 84, 825-889 (2010).
26. Puneet, P. et al. SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science 328, 1290-1294 (2010).
27. Greco, W.R., Bravo, G. & Parsons, J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385 (1995).
28. Lehár, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659-666 (2009).
29. Zimmermann, G.R., Léhar, J. & Keith, C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12, 34-42 (2007). (Pubitemid 46014485)
30. Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7, 348-350 (2011).
31. Knight, Z.A., Lin, H. & Shokat, K.M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130-137 (2010).
32. Oda, K. & Kitano, H. A comprehensive map of the toll-like receptor signaling network. Mol. Syst. Biol. 2, 2006.0015 (2006).
33. Bornkamp, B. et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J. Biopharm. Stat. 17, 965-995 (2007). (Pubitemid 350135825)
34. Jia, J. et al. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8, 111-128 (2009); erratum 8, 516 (2009).
35. Fitzgerald, J.B., Schoeberl, B., Nielsen, U.B. & Sorger, P.K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 (2006). (Pubitemid 44266307)
36. Sun, C.-P. et al. Integrative systems control approach for reactivating Kaposi's sarcoma-associated herpesvirus (KSHV) with combinatory drugs. Integr. Biol. (Camb) 1, 123-130 (2009).
37. Wong, P.K. et al. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc. Natl. Acad. Sci. USA 105, 5105-5110 (2008).
38. Feala, J.D. et al. Systems approaches and algorithms for discovery of combinatorial therapies. Wiley Interdiscip. Rev. Syst. Biol. Med. 2, 181-193 (2010).
39. Chatterjee, M.S., Purvis, J.E., Brass, L.F. & Diamond, S.L. Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli. Nat. Biotechnol. 28, 727-732 (2010).
40. Geva-Zatorsky, N. et al. Protein dynamics in drug combinations: a linear superposition of individual-drug responses. Cell 140, 643-651 (2010).
41. Horackova, M., Ponka, P. & Byczko, Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H2O2 injury in adult cardiomyocytes. Cardiovasc. Res. 47, 529-536 (2000). (Pubitemid 30646074)
42. Sindrilaru, A. et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Invest. 121, 985-997 (2011).
43. Hammaker, D. & Firestein, G.S. "Go upstream, young man": lessons learned from the p38 saga. Ann. Rheum. Dis. 69 (suppl. 1), i77-i82 (2010).
44. Dobson, P.D. & Kell, D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug Discov. 7, 205-220 (2008). (Pubitemid 351321232)
45. Kell, D.B. & Oliver, S.G. Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays 26, 99-105 (2004). (Pubitemid 38095354)
46. Scully, P. et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am. J. Gastroenterol. 105, 2235-2243 (2010).
47. Löfdahl, C.-G. COPD and co-morbidities, with special emphasis on cardiovascular conditions. Clin. Respir. J. 2 (suppl. 1), 59-63 (2008).
48. Akella, L.B. & DeCaprio, D. Cheminformatics approaches to analyze diversity in compound screening libraries. Curr. Opin. Chem. Biol. 14, 325-330 (2010).
49. Tobinick, E.L. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 22, 119-125 (2009).
50. Hughes, J. Evolutionary multi-objective ranking with uncertainty and noise. in Evolutionary Multi-Criterion Optimization, Vol. 1993 (eds. Zitzler, E. et al.) 329-343 (Springer, 2001).